AION Labs Launches New Platform to Reduce Time and Cost of Antibody Development
The platform will allow for a more direct method of antibody optimization.
stock.adobe.com
The AI revolution continues.
A new start up in Israel plans to improve the ways that antibodies are developed in an attempt to fully optimize the drug development process. AION Labs is developing an AI-powered platform known as CombinAble.AI.1 The platform uses the algorithmic technology to produce high quality biomolecules simulations.
The hope is that this will reduce both the time it takes and the cost of developing new antibodies.
In a press release, CombinAble co-founder and CEO Daria Kokh, PhD, said, “Our emphasis is on combining various advanced machine learning models, including large protein language models, molecular dynamics simulations and multi-objective optimization algorithms, integrating them into a single unified solution for targeted antibody discovery. AION Labs' resources and expertise have been pivotal in shaping our company, providing the material and logistical support to help us refine our scientific strategy, and expand the team. As we progress, the knowledge and insights provided by its pharmaceutical partners will be invaluable for the development and commercialization of our solution."
In the same press release, AION Labs CEO Mati Gill also said, “The launch of CombinAble heralds a shift in the approach to targeted antibody design by leveraging AI to optimize and expedite the discovery process. We are delighted to welcome CombinAble into the AION Labs ecosystem and look forward to working closely with the team to develop solutions that enable the design of highly effective biological therapeutics."
According to the company, the process known as antibody optimization allows them take a newly discovered antibody and then enhance it by adjusting characteristics related to safety, efficacy, and manufacturability. The CombinAble system is able to learn from data and physics-based principles to search out solutions. Hopefully, it will be able to transform the process from a trial-and-error method to a more direct style.
The goal is to be able to automate the process of optimizing antibodies to free up researchers developing or searching for new antibodies.
Source
- AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development. AION Labs. March 12, 2024. Accessed March 13, 2024. https://www.prnewswire.com/news-releases/aion-labs-launches-combinableai-to-reduce-time-and-cost-of-targeted-antibody-design-advancing-optimization-of-drug-development-302086581.html
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
